Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase I, Open-label, Multi-arm, Multi-centre, Multi-dose, Dose Escalation Study of LTX-315 as Monotherapy or in Combination With Either Ipilimumab or Pembrolizumab in Patients With Transdermally Accessible Tumours

NCT01986426 is registered in ClinicalTrials.gov with Lytix Biopharma AS as lead sponsor.

NCT NCT01986426
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT01986426 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase I, Open-label, Multi-arm, Multi-centre, Multi-dose, Dose Escalation Study of LTX-315 as Monotherapy or in Combination With Either Ipilimumab or Pembrolizumab in Patients With Transdermally Accessible Tumours
Lead sponsor
Lytix Biopharma AS
Phase
Phase 1
Overall status
Completed
Start date
November 30, 2013
Completion date
August 31, 2018
Enrollment
80 (estimated)
Sites
14

Conditions

As the registry lists them; a condition with its own page is linked.

breast cancer, cancer, head and neck cancer, lymphoma, melanoma, triple-negative breast cancer